Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder

Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder of the central nervous system characterized by recurrent, disabling attacks that affect the optic nerve, spinal cord, and brain/brainstem. While rituximab, targeting CD20-positive B-cells, is used as an off-label therapy fo...

ver descrição completa

Detalhes bibliográficos
Principais autores: Benjamin Osborne, Gabriela Romanow, J. Michael Hemphill, Myassar Zarif, Tracy DeAngelis, Tyler Kaplan, Unsong Oh, Johnathan Pinkhasov, Kristina Patterson, Michael Levy
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2024-04-01
coleção:Frontiers in Neurology
Assuntos:
neuromyelitis optica spectrum disorder
aquaporin-4 antibody
inebilizumab
rituximab
treatment transition
clinical outcome
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fneur.2024.1352779/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2024.1352779/full

Registros relacionados